Primerica Stock Hits New 52-Week Low (PRI)

NEW YORK ( TheStreet) -- Primerica (NYSE: PRI) hit a new 52-week low Thursday as it is currently trading at $19.24, below its previous 52-week low of $19.31 with 13,500 shares traded as of 10:12 a.m. ET. Average volume has been 281,300 shares over the past 30 days.

Primerica has a market cap of $1.5 billion and is part of the financial sector and insurance industry. Shares are down 19.9% year to date as of the close of trading on Wednesday.

Primerica, Inc., together with its subsidiaries, engages in the distribution of financial products on behalf of third parties to middle income households in the United States and Canada. The company has a P/E ratio of 8.3, below the average insurance industry P/E ratio of 9.5 and below the S&P 500 P/E ratio of 17.7.
  • Practice your PRI trading strategies and win cash in our stock game.

TheStreet Ratings rates Primerica as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. You can view the full Primerica Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

Don't Panic! The Risk of a Recession This Year Is Low

Don't Panic! The Risk of a Recession This Year Is Low

Even Standing Desk Company Varidesk Is Watching How the Trump Tariffs Play Out

Even Standing Desk Company Varidesk Is Watching How the Trump Tariffs Play Out

State Street Gets Pummeled on Software Deal; Pizza Wars Are Raging -- ICYMI

State Street Gets Pummeled on Software Deal; Pizza Wars Are Raging -- ICYMI

Schlumberger Stock Dips as Investors Ignore Start of 'Earnings Liftoff'

Schlumberger Stock Dips as Investors Ignore Start of 'Earnings Liftoff'

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant